NASDAQ:ALPN - Free Report ) by 10.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 819,275 shares of the biotechnology company's stock after selling 95,638 shares during the period. Alpine Immune Sciences comprises approximately 1.3% of Vivo Capital LLC's holdings, making the stock its 14th largest position. Vivo Capital LLC owned 1.41% of Alpine Immune Sciences worth $15,615,000 at the end of the most recent quarter.
Get Alpine Immune Sciences alerts:
Sign Up
Other large investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its holdings in Alpine Immune Sciences by 27.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 297,452 shares of the biotechnology company's stock valued at $5,669,000 after buying an additional 63,196 shares in the last quarter. AJOVista LLC bought a new position in shares of Alpine Immune Sciences during the 4th quarter valued at about $64,000. Swiss National Bank boosted its holdings in shares of Alpine Immune Sciences by 35.5% during the 4th quarter. Swiss National Bank now owns 57,200 shares of the biotechnology company's stock valued at $1,090,000 after purchasing an additional 15,000 shares during the last quarter. New York State Common Retirement Fund increased its holdings in shares of Alpine Immune Sciences by 54.4% in the fourth quarter. New York State Common Retirement Fund now owns 14,875 shares of the biotechnology company's stock worth $284,000 after purchasing an additional 5,241 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in Alpine Immune Sciences during the 4th quarter valued at approximately $2,689,000. 75.17% of the stock is currently owned by hedge funds and other institutional investors.
Alpine Immune Sciences Stock Performance ALPN stock traded up $0.12 during trading on Thursday, reaching $64.82. 1,141,350 shares of the company traded hands, compared to its average volume of 1,896,612. The business has a 50 day simple moving average of $48.61 and a 200 day simple moving average of $29.78. Alpine Immune Sciences, Inc. has a 12 month low of $7.55 and a 12 month high of $64.85. The company has a market capitalization of $4.25 billion, a price-to-earnings ratio of -101.28 and a beta of 0.97.
Alpine Immune Sciences (NASDAQ:ALPN - Get Free Report ) last posted its earnings results on Monday, March 18th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The company had revenue of $30.85 million during the quarter, compared to analysts' expectations of $6.90 million. As a group, research analysts forecast that Alpine Immune Sciences, Inc. will post -1.74 EPS for the current year.
Analyst Ratings Changes A number of research firms have recently commented on ALPN. HC Wainwright downgraded Alpine Immune Sciences from a "buy" rating to a "neutral" rating in a research report on Thursday, April 11th. TD Cowen reiterated a "hold" rating on shares of Alpine Immune Sciences in a research report on Tuesday, April 16th. Leerink Partnrs lowered Alpine Immune Sciences from an "outperform" rating to a "market perform" rating in a research note on Thursday, April 11th. Royal Bank of Canada restated a "sector perform" rating and issued a $65.00 target price (up previously from $41.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Finally, Morgan Stanley reissued an "equal weight" rating and issued a $65.00 price objective (up previously from $47.00) on shares of Alpine Immune Sciences in a research note on Thursday, April 11th. Eight research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $50.33.
View Our Latest Stock Analysis on ALPN
About Alpine Immune Sciences (
Free Report )
Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.
Recommended Stories
Before you consider Alpine Immune Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpine Immune Sciences wasn't on the list.
While Alpine Immune Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
